Roy Buchanan
Stock Analyst at JMP Securities
(5.00)
# 16
Out of 5,138 analysts
54
Total ratings
59.42%
Success rate
103.46%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $29.91 | +27.05% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $15.62 | +104.87% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $13.35 | +87.27% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $4.39 | +218.91% | 2 | Jun 17, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.25 | +60.00% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.58 | +1,039.24% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $67.27 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $3.13 | +27.80% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $4.52 | +209.73% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $116.80 | -71.75% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.70 | +6.38% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $813.24 | -44.91% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $7.01 | +128.25% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.21 | - | 2 | Feb 16, 2023 |
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $29.91
Upside: +27.05%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $15.62
Upside: +104.87%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $13.35
Upside: +87.27%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $4.39
Upside: +218.91%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.25
Upside: +60.00%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.58
Upside: +1,039.24%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $67.27
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $3.13
Upside: +27.80%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $4.52
Upside: +209.73%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $116.80
Upside: -71.75%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.70
Upside: +6.38%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $813.24
Upside: -44.91%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $7.01
Upside: +128.25%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.21
Upside: -